SCHEMBL4196369

SCHEMBL4196369

[CH2]NCc1ccccc1NC(C)=O

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.52
HPGD P15428 1/20 0.52
MAPK1 P28482 1/20 0.49
TSPO P30536 1/20 0.48
TSHR P16473 2/20 0.47
HTT P42858 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
SIRT1 Q96EB6 1/20 0.47
POLB P06746 1/20 0.46
CYP2C19 P33261 1/20 0.46
KDM4E B2RXH2 1/20 0.46
LMNA P02545 1/20 0.46
BRD4 O60885 1/20 0.44
MAPT P10636 1/20 0.43
FEN1 P39748 1/20 0.43
HSD17B10 Q99714 2/20 0.43
MAOA P21397 1/20 0.42
NAPRT Q6XQN6 1/20 0.42
NPC1 O15118 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9222061 0.84 ALDH1A1 (0.53) ALDH1A1HPGDMAPK1TSHRHTT
SCHEMBL8537169 0.83 ALDH1A1 (0.49) ALDH1A1HPGDMAPK1TSPOTSHR
SCHEMBL840362 0.81 ALDH1A1 (0.55) ALDH1A1HPGDMAPK1TSPOTSHR
SCHEMBL1644965 0.81 MAPK1 (0.59) ALDH1A1HPGDMAPK1TSHRHTT
SCHEMBL2936941 0.81 ALDH1A1 (0.55) ALDH1A1HPGDMAPK1TSHRHTT
SCHEMBL7055476 0.79 ALDH1A1 (0.57) ALDH1A1HPGDMAPK1TSPOTSHR
SCHEMBL3150784 0.79 ALDH1A1 (0.59) ALDH1A1HPGDMAPK1TSPOTSHR
SCHEMBL30168125 0.79 ALDH1A1 (0.59) ALDH1A1HPGDMAPK1TSPOTSHR
SCHEMBL8421119 0.79 ALDH1A1 (0.52) ALDH1A1HPGDMAPK1TSPOTSHR
SCHEMBL19924420 0.78 ALDH1A1 (0.55) ALDH1A1HPGDMAPK1TSPOTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1796675-A4 COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC DISEASES MERCK & CO INC (US) 2009-03-04 EP disclosed
US-20080096859-A1 Compositions and Methods for Treating Ophthalmic Diseases MERCK SHARP & DOHME CORP. 2008-04-24 US disclosed
EP-1796675-A2 COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC DISEASES Merck & Co., Inc. (US) 2007-06-20 EP disclosed
WO-2006039252-A2 COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC DISEASES MERCK & CO., INC. (US) 2006-04-13 WO disclosed
US-6127388-A Azetidine, pyrrolidine and piperidine derivatives as 5-HT1D receptor agonists MERCK SHARP & DOHME LTD. (GB) 2000-10-03 US disclosed
US-6025374-A Azetidine, pyrrolidine and piperidine derivatives as 5HT1 receptor agonists MERCK SHARP & DOHME, LTD. (GB) 2000-02-15 US disclosed
US-5998440-A Azetidine, pyrrolidine and piperidine derivatives MERCK SHARPE & DOHME LTD. (GB) 1999-12-07 US disclosed
US-5854268-A Azetidine, pyrrolidine and piperidine derivatives MERCK SHARP & DOHME, LTD. (GB) 1998-12-29 US disclosed
US-5849746-A Substituted 1,4-piperazine-heteroaryl derivatives as 5-HT1D receptor agonists MERCK SHARP & DOHME LTD. (GB) 1998-12-15 US disclosed
EP-0861244-A1 AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES MERCK SHARP & DOHME LTD. (GB) 1998-09-02 EP disclosed
EP-0807109-A1 SUBSTITUTED 1,4-PIPERAZINE-HETEROARYL DERIVATIVES AS 5-HT 1D? RECEPTOR AGONISTS MERCK SHARP & DOHME LTD. (GB) 1997-11-19 EP disclosed
EP-0804434-A1 AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES MERCK SHARP & DOHME LTD. (GB) 1997-11-05 EP disclosed
EP-0796258-A1 AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES AS 5HT1 RECEPTOR AGONISTS MERCK SHARP & DOHME LTD. (GB) 1997-09-24 EP disclosed
WO-1997018201-A1 AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES MERCK SHARP & DOHME LIMITED (GB) 1997-05-22 WO disclosed
WO-1996023785-A1 SUBSTITUTED 1,4-PIPERAZINE-HETEROARYL DERIVATIVES AS 5-HT1D RECEPTOR AGONISTS MERCK SHARP & DOHME LIMITED (GB) 1996-08-08 WO disclosed
WO-1996017842-A1 AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES AS 5HT1 RECEPTOR AGONISTS MERCK SHARP & DOHME LIMITED (GB) 1996-06-13 WO disclosed
WO-1996004274-A1 AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES MERCK SHARP & DOHME LIMITED (GB) 1996-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096859-A1 Compositions and Methods for Treating Ophthalmic Diseases CXCL12, CXCR4, CX3CR1 ALDH1A1 2142/4885HPGD 489/4885MAPK1 671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.